Beyond conventional therapies: the evolution of targeted agents and immunotherapies in triple-negative breast cancer

Review Open access Aug 2026

Current and future therapies for triple-negative breast cancer

This framework integrates evidence level, disease stage, biomarker reliability and patient tolerance into treatment selection for TNBC precision therapy and distinguish them from maturing or exploratory strategies such as pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death...

Zi-Xun Wang, Xi-Yu Liu, Yu-Xiao Wu et al. · Journal of Hematology & Onco... · 0 citations

Save

Copy APA Copied ✓ Copy MLA Copied ✓ Copy BibTeX Copied ✓

Review Open access Aug 2026

Optimizing immunotherapy–radiotherapy synergy in triple-negative breast cancer: mechanisms, clinical evidence, and therapeutic windows

The immunological characteristics of TNBC, the current status of ICI-based therapy, and the underlying mechanisms of resistance are reviewed, which summarizes the biological rationale for combining RT with ICIs in the treatment of TNBC and explores the impact of different RT dose-fractionation regimens, treatment seque...

Lu Wang, Xin Bai, Fan Wang et al. · Frontiers in Immunology · 0 citations

Save

Copy APA Copied ✓ Copy MLA Copied ✓ Copy BibTeX Copied ✓

Review Aug 2026

Advances in Targeting Immune Checkpoint Inhibitors and New Vaccination Strategies for Triple-negative Breast Cancers: An Update.

This review highlights advancements in immunotherapy strategies for mitigating TNBC, with a particular focus on targeting immunosuppressive molecules.

Parth Malik, V. Patel, R. Maitra et al. · Current Drug Targets · 0 citations

Save

Copy APA Copied ✓ Copy MLA Copied ✓ Copy BibTeX Copied ✓

Review Open access Aug 2026

Emerging Therapeutic Strategies in Small-Cell Lung Cancer: From Adaptive Resistance to Precision Therapy

The evolving biological basis of therapeutic resistance is examined and how emerging treatment strategies may be integrated into biologically informed clinical development is discussed to improve patient selection, guide therapeutic sequencing, and increase the durability of treatment benefit in extensive-stage SCLC.

Jun Kim, Seounghun Kang · Pharmaceuticals · 0 citations

Save

Copy APA Copied ✓ Copy MLA Copied ✓ Copy BibTeX Copied ✓

Conference Open access Aug 2026

Advances in Molecular Subtype-Based Precision Therapy and Strategies to Overcome Resistance in Breast Cancer

Breast cancer is a leading cause of cancer -related morbidity and mortality, characterized by significant biological and molecular heterogeneity. Molecular subtypes —including luminal A, luminal B, HER2 - enriched, and triple -negative—inform prognosis and guide prec ision therapies. Despite advances with endocrine age...

Yeyao Lu · Exploring Science Academic C... · 0 citations

Save

Copy APA Copied ✓ Copy MLA Copied ✓ Copy BibTeX Copied ✓

Review Open access Sep 2026

Molecular subgroups and biomarker guided precision immunotherapy in triple-negative breast cancer: advances, challenges, and future directions

A precision immunotherapy framework that integrates TNBC molecular subgroups, validated and dynamic biomarker models, rational combinations, resistance mechanisms, and emerging tools is proposed, including single-cell sequencing, spatial transcriptomics, multi-omics, and AI-assisted stratification to improve response d...

Shun-Hao Peng, Meng-Yao Qin, G. Song et al. · Frontiers in Immunology · 0 citations

Save

Copy APA Copied ✓ Copy MLA Copied ✓ Copy BibTeX Copied ✓